Evidence map›Paper›PMID 30689886›Full record

ArticleInternational immunology2019

Cholera toxin B induces interleukin-1β production from resident peritoneal macrophages through the pyrin inflammasome as well as the NLRP3 inflammasome.

Takashi Orimo, Izumi Sasaki, Hiroaki Hemmi, Toshiya Ozasa, Yuri Fukuda-Ohta, Tomokazu Ohta, Mio Morinaka, Mariko Kitauchi, Takako Yamaguchi, Yayoi Sato and 12 more

Open access · greenAbstract read
In one paragraph

Article in International immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Inflammasomes as Targets for Adjuvants.Pathogens (Basel, Switzerland) · 2020
    Review
  9. Virulence Regulation and Innate Host Response in the Pathogenicity ofFrontiers in cellular and infection microbiology · 2020
    Review
  10. Article
  11. El Tor BiotypeFrontiers in immunology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 1 country.

Takashi OrimoDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Izumi SasakiDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Hiroaki HemmiDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Toshiya OzasaDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Yuri Fukuda-OhtaDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Tomokazu OhtaDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Mio MorinakaDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Mariko KitauchiDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Takako YamaguchiLaboratory for Immune Regulation, World Premier International Research Center Initiative, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Yayoi SatoLaboratory for Immune Regulation, World Premier International Research Center Initiative, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Takashi TanakaLaboratory for Inflammatory Regulation, RIKEN Center for Integrative Medical Science (IMS-RCAI), Yokohama, Kanagawa, Japan.
Katsuaki HoshinoDepartment of Immunology, Faculty of Medicine, Kagawa University, Miki, Kagawa, Japan.
Kei-Ichi KatayamaDepartment of Molecular Cell Biology and Molecular Medicine, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Shinji FukudaInstitute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
Kensuke MiyakeDivision of Innate Immunity, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Masahiro YamamotoDepartment of Immunoparasitology, Research Institute for Microbial Diseases, WPI Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Takashi SatohDepartment of Host Defense, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Koichi FurukawaDepartment of Lifelong Sports and Health Sciences, Chubu University College of Life and Health Sciences, Kasugai, Aichi, Japan.
Etsushi KurodaLaboratory of Adjuvant Innovation, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, Japan.
Ken J IshiiLaboratory of Adjuvant Innovation, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, Japan.
Kiyoshi TakedaLaboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Tsuneyasu KaishoDepartment of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
Wakayama Medical University · JPThe University of Osaka · JPNational Institute of Biomedical Innovation, Health and Nutrition · JPOsaka International University · JPChubu University · JPKagawa University · JPRIKEN Center for Integrative Medical Sciences · JPThe University of Tokyo · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholera toxin B (CTB) is a subunit of cholera toxin, a bacterial enterotoxin secreted by Vibrio cholerae and also functions as an immune adjuvant. However, it remains unclear how CTB activates immune cells. We here evaluated whether or how CTB induces production of a pro-inflammatory cytokine, interleukin-1β (IL-1β). CTB induced IL-1β production not only from bone marrow-derived macrophages (BMMs) but also from resident peritoneal macrophages in synergy with O111:B4-derived lipopolysaccharide (LPS O111:B4) that can bind to CTB. Meanwhile, when prestimulated with O55:B5-derived LPS (LPS O55:B5) that fails to bind to CTB, resident peritoneal macrophages, but not BMMs, produced IL-1β in response to CTB. The CTB-induced IL-1β production in synergy with LPS in both peritoneal macrophages and BMMs was dependent on ganglioside GM1, which is required for internalization of CTB. Notably, not only the NLRP3 inflammasome but also the pyrin inflammasome were involved in CTB-induced IL-1β production from resident peritoneal macrophages, while only the NLRP3 inflammasome was involved in that from BMMs. In response to CTB, a Rho family small GTPase, RhoA, which activates pyrin inflammasome upon various kinds of biochemical modification, increased its phosphorylation at serine-188 in a GM1-dependent manner. This phosphorylation as well as CTB-induced IL-1β productions were dependent on protein kinase A (PKA), indicating critical involvement of PKA-dependent RhoA phosphorylation in CTB-induced IL-1β production. Taken together, these results suggest that CTB, incorporated through GM1, can activate resident peritoneal macrophages to produce IL-1β in synergy with LPS through novel mechanisms in which pyrin as well as NLRP3 inflammasomes are involved.

Indexed as

AnimalsCholera ToxinHumansInflammasomesInterleukin-1betaMacrophages, PeritonealNLR Family, Pyrin Domain-Containing 3 ProteinPyrinCholera ToxinInflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinPyrincholera toxin Binterleukin-1βpyrin inflammasome

Identifiers

PMID30689886
PMCPMC6749887
OpenAlexW2911531686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.